Zymeworks

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Zymeworks and other ETFs, options, and stocks.

About ZYME

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2).

CEO

Kenneth Harry Galbraith

CEOKenneth Harry Galbraith

Employees

277

Employees277

Headquarters

Middletown, Delaware

HeadquartersMiddletown, Delaware

Founded

2003

Founded2003

Employees

277

Employees277

ZYME Key Statistics

Market cap

991.03M

Market cap991.03M

Price-Earnings ratio

-9.48

Price-Earnings ratio-9.48

Dividend yield

—

Dividend yield—

Average volume

512.40K

Average volume512.40K

High today

$14.54

High today$14.54

Low today

$13.57

Low today$13.57

Open price

$13.74

Open price$13.74

Volume

507.03K

Volume507.03K

52 Week high

$17.70

52 Week high$17.70

52 Week low

$7.97

52 Week low$7.97

ZYME News

Seeking Alpha 2d

Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zymeworks (NASDAQ:ZYME) announced Thursday the FDA approval of their jointly developed bispecific antibody Ziihera as a l...

Analyst ratings

63%

of 8 ratings

Buy

62.5%

Hold

37.5%

Sell